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Abstract
Background: A new vaccine against Rotavirus (RV) gastroenteritis was introduced in Germany in 2006. In 1997 the
first RV vaccine was withdrawn due to an increased incidence in intussusception (IS). Thus, an accurate estimation
of the incidence of IS is important for post-licensure surveillance.
Methods: IS-Data were obtained from the ‘Erhebungseinheit für seltene pädiatrische Erkrankungen Deutschland’
(ESPED, German surveillance unit for rare pediatric diseases) collaborations’ central register where all cases of
intussusception in Germany for the years 2006 and 2007 are collected (n = 1200). In order to obtain an unbiased
estimate of the incidence, it is necessary to determine the population under risk out of which these cases originated,
and the proportion of real cases not reported to the registry (underreporting). In order to assess underreporting, a
random sample of 31 hospitals was re-assessed by an outside reviewer. The estimation of incidence was done using
a single Maximum-Likelihood (ML) estimator based on data from both the registry and the sample.
Results: The uncorrected observed incidence was calculated to be 26.6/100,000 child-years for children below
1 year old, 23.8 for those below 2 years old, and 5.2 for those below 15 years old. The review revealed a mean
reporting quota of about 41% and the ML approach yielded an incidence of 51.5/100,000 child-years (95%CI
[41.7;61.1]) for children below 2 years of age.
Conclusions: While substantial under-reporting led to very conservative estimates of the IS incidence, the
approach described here allows an accurate estimation of IS incidence including corresponding confidence bands.
Therefore, ML estimation is a straightforward instrument to derive stable, unbiased estimates in epidemiological
studies with incomplete data.
Background
Intussusception (IS) is characterized by the inversion of
an intestinal section into an adjacent intestinal section
[1]. Main symptoms are abdominal pain, abdominal
resistance and bloody tinged defecation. IS leads to
obstruction of bowel passage and the venous blood flow,
resulting in a sudden onset of colicky abdominal pain,
and constriction of the mesentery [2]. Classification of
IS occurs by demonstration of intestinal invagination via
surgery, radiology, and/or autopsy. Incidence data on IS
show a wide variation, ranging from 35 (Brazil) to 1200/
100,000 child-years (United Kingdom) for children
below 1 year [3] which is mainly due to the lack of a
standardized case definition. Only recently diagnostic
guidelines were defined by the Brighton Collaboration
Working Group [1].
The importance of accurate incidence estimation on
the base of standardized diagnostic criteria is even more
important on the background of vaccination against
Rotavirus (RV) gastroenteritis. This is because the first
vaccine against RV, a tetravalent, rhesus-based rotavirus
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and Drug Administration in 1998, was withdrawn from
the market following reports of IS among recently vacci-
nated children [2]. Nevertheless, more than 600,000
infants received at least one dose [4]. At that time the
risk of IS related to the vaccine has been estimated to
be anywhere between 1 in 4,670 and 1 in 32,000 vacci-
nated children [2,5,6].
Just recently, two new RV vaccines, Rotarix© and Rota-
Teq©, have been introduced on the market. To provide a
clear epidemiological statement about IS following vacci-
nation, the incidence of IS has to be determined prior to
global introduction of these new vaccines in order to
establish baseline disease incidence rates and allow for
interpretation of post-licensure IS surveillance data [7].
Between January 1, 2006, and December 31, 2007, a
nationwide, active hospital based, multicenter surveil-
lance study was conducted by ESPED to determine the
incidence of IS in Germany. Even though more than 99%
of all German pediatric hospitals participated, one chal-
lenge in this study and for surveillance studies in general,
was potential incomplete reporting of IS cases. This
might result in an underestimation of the incidence.
A similar but much smaller study was recently per-
formed in Switzerland. Uncorrected IS incidence
obtained from this surveillance was refined by means of
a Capture-Recapture analysis [8]. After correction, the
incidence of IS was estimated to be 56/100,000 child-
years in children below 1 year compared to 38/100,000
initially and 46/100,000 for children below 2 years of
age compared to 31/100,000 initially.
We expected similar under-reporting in Germany, so
we decided to estimate the fraction of reported cases by a
thorough review of a 10% random sample of the partici-
pating hospitals. It was assumed that the distribution of
under-reporting in the random sample corresponds to
the distribution of under-reporting in the annual inci-
dence estimated through the ESPED surveillance.
Thereby it was possible to calculate adjusted incidence
estimates for a given age group.
Since it was necessary to include several probabilistic
steps in the generation of the data, the necessary model
is rather complex. The model has to include the true
(random) number of cases in a hospital’sp o p u l a t i o n
under risk, and must also allow randomness of the
reporting quota of a hospital. This reporting quota is
not identical for all hospitals, but can be modeled as a
random realization based on the binomially distributed
number of reported cases (using the true number of
cases and the true reporting quote of the hospital as
parameters). Two groups of clinics have to be distin-
guished according to the availability of the true number
of IS cases, i.e. those hospitals included in the sample
where the true reporting quota is available and the hos-
pitals not in the sample where this is not the case. It is
not possible to fit this rather complicated data model
into a standard method. Instead, a more sophisticated
statistical analysis is required which is provided by maxi-
mum likelihood estimation.T h i sm e t h o di sc o m m o n l y
used for complicated data structures such as phenotype
analysis in genetic applications (cf. e.g. [9,10]). To our
knowledge, it has never been used so far for estimation
of clinical incidence. The basic idea of this method is to
compute the probability of observing data for all possi-
ble values of the parameter which is to be estimated (i.e.
the incidence a). In this paper we describe our method
for the estimation of a, followed by an explanation of
the construction of the associated confidence bands by
bootstrap methods. Finally, we use the method to deter-
mine estimates of the incidence and their associated
confidence intervals.
Methods
ESPED study period and study design
This study was a prospective, hospital-based, multicenter
surveillance study conducted from January 1, 2006 to
December 31, 2007. The study protocol was approved
by the institutional review board and the ethics commit-
tee of Witten/Herdecke university and also approved by
the data protection commission of the state of North
Rhine Westfalia.
Study population
The target population for this study were children under
15 years of age with a diagnosis of IS reported to ESPED
by participating pediatric medical care providers during
the study. However, the aim is to obtain an estimate for
the incidence of IS valid for all children below 15 years
in Germany.
Inclusion criteria
IS cases were included if the defined eligibility criteria
given below were met:
￿ male or a female child below 15 years of age at the
time of enrolment into the study
￿ subject fulfilling Brighton Collaboration’sG r o u p
Criteria (version dated January 30,2002) for definite
IS [1]
￿ IS diagnosis occurring during the two years study
period.
Exclusion criteria
Patients were not included as IS cases if the criteria
below were met:
Bissantz et al. BMC Gastroenterology 2011, 11:26
http://www.biomedcentral.com/1471-230X/11/26
Page 2 of 9￿ diagnosis of IS based solely on clinical signs and
symptoms
￿ means for diagnosis of IS cannot be determined.
ESPED data collection
The ESPED reporting system
Data were collected by ESPED, which performs active
surveillance of rare pediatric conditions in Germany
based on monthly contact to pediatric care providers.
More than 99% of the pediatric departments in Germany
(including departments for pediatric surgery) are mem-
bers of ESPED for at least one of the medical conditions
under observation. The ESPED system has just recently
been reviewed and was found to have generated more
than 100 publications between January 1992 and August
2008. Seven of those publications had an impact factor
above 10. Generally, more than 90% of all German pedia-
tric hospitals participated in surveillance studies if the
principal investigator was supported by staff comprising
at least two persons or if the mailing of the questionnaire
was handled by the ESPED office - as in this study [11].
The participating hospitals complete an internet based
form with a list of conditions under observation and
send this back to ESPED electronically (see Figure 1).
Reports received by the Unit’s Scientific Coordinator
at ESPED headquarters are forwarded to appropriate
investigators depending on the reported condition.
For this study, trial reports on IS were forwarded to
the IS study Principal Investigator in Wuppertal, who
contacted the reporting clinicians directly for comple-
tion of a detailed follow-up questionnaire. These follow-
up questionnaires were directly returned to the IS study
principal investigator. To ensure return of all completed
follow-up questionnaires, all hospitals with at least three
missing questionnaires were personally visited by a med-
ical student.
To get an unbiased estimation of the distribution of
under-reporting, a random sample of 46 out of the 336
participating hospitals was asked to review all cases of
IS between Jan. 1, 2006 and Dec. 31, 2007. Thirty-one
hospitals agreed to allow review of their data. The
review was done by a trained medical student who
reviewed the ICD-10 and OPS codes in the clinic regis-
ter and did a retrospective assessment of all eligible
patients based on the medical record for fulfilling the
Brighton Collaboration Group Criteria for IS diagnosis
(level 1). For each identified case of IS, the following
information was submitted: gender, date of admission,
birth month and year. Based on these variables the
reviewed cases were compared with the cases which had
been originally reported to ESPED surveillance for each
hospital. Thus, an estimate of the underreporting rate
for each hospital in the sample is possible. With the dis-
tribution of under-reporting rates in the sample and the
original ESPED surveillance annual incidence, it is possi-
ble to calculate adjusted estimates for a given age group.
Statistical analysis
Estimation of the corrected IS incidence
An uncorrected estimation of the incidence as the ratio
between the annual number of IS cases reported
through the ESPED network and the number of children
at risk (provided by the “Statistisches Bundesamt, the
German Federal Office for Statistics, for 2006” [12])
might lead to under-estimation of IS incidence due to
under-reporting of cases. Therefore, we used a maxi-
mum likelihood approach for the estimation of the cor-
rected incidence taking under-reporting into account.
1. Determination of the population under risk To
determine the population under risk, i.e. the number of
children of the corresponding age group within the
catchment area of a given hospital, five different models
were developed with the aim of modelling the probabil-
ity that a specific hospital is visited in case of IS. To this
end we used administrative district population data for
children below 15 years of age obtained from the ‘Statis-
tisches Bundesamt’ [12]. The following models were
used:
￿ v0: The population under risk corresponds to the
fraction of pediatric beds of a hospital relative to the
overall number of such beds in Germany [13] based
on the ‘Krankenhausbedarfsplanung’ (a forecast on
the need of hospitals and pediatric beds). The num-
ber of beds was calculated as sum of pediatric and
pediatric surgery beds; pediatric cardiology and neo-
natology beds were not included.
The models v1 to v4 include the distance to a hospital
as a potential factor influencing the choice of the hospital,
and its degree of specialization. The distance rij of hospital
i from the centre of a district j was determined from GPS
coordinates, where hospitals more than 50 km away from
Figure 1 Structure of the ESPED reporting system (IS reporting).
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factor included was the degree of specialization as a mea-
sure of a hospital’s quality for IS treatment. Hospitals were
labelled type 1, 2 and 3 if they had ≤400, 400 - 800, or
>800 beds, respectively, with pediatric hospitals always
being of type 3.
￿ v1: The fraction of an administrative areas’ popula-
tion choosing a specific hospital is inversely propor-
tional to the distance, with an additional weighting
based on its specialization (weight factor 2/3, 3/3,
4/3 for type 1/2/3 respectively).
￿ v2: Similar to v1, but using the squared distance
instead.
￿ v3: As v1, but using third power of distance.
￿ v4: Similar to v2 but using modified weights (8/9;
1; 10/9), thus reducing the impact of specialization.
2. Maximum likelihood estimation of the global inci-
dence a We use the following notation:
Bi : population within the catchment area of hospital
i for a fixed population model vj, j = 0,...,4
Ki :n u m b e ro f“all” cases within the catchment area
of hospital i (true number)
Mi : number of reported cases of hospital i
pi : “reporting quota” of hospital i (if available)
a: global incidence of IS
The random model for the data is as follows. The true
number of IS cases for a hospital Ki is Poisson distribu-
ted with parameter a. Bi, i.e.
Ki ∼ poiss(α · Bi)withprobabilityfunctionPPoiss(x;α · Bi).
F o rh o s p i t a l sf o rw h i c ht h et r u en u m b e ro fc a s e si s
unknown, the reported number Mi is binomially distrib-
uted with Ki attempts and probability pi:
Mi ∼ B(pi;Ki)withprobabilityfunctionPBin(x;pi,Ki).
The reporting quota pi are assumed to be independent
and identically distributed between hospitals, i.e. pi~V(p)
with density function v(p), for all hospitals, and also
independent of Ki. Refer to Figure 2 for a plot of the
empirical distribution function V(P) of the reporting
quota p.
The maximum likelihood estimator for the incidence is
based on the likelihood function L(a), i.e. the probability
to observe the data given the respective value of the inci-
dence a. Hospitals in the sample with Ki available are
treated separately from hospitals for which only Mi is
known. Consequently, we are concerned with the pro-
duct of two separate likelihood functions L1(a) and L2(a).
The likelihood L1 for hospitals in the sample with
known Mi and Ki is
L1 (α) =
n1  
i=1
PBin
 
Mi,Ki;pi
 
· PPoiss (Ki;(α · Bi))
For the second group of hospitals only the number of
reported IS cases Mi is available. To deal with the lack
of knowledge about the actual distribution of under-
reporting of IS cases V(p) we estimate it from the
observed under-reporting rates in the first group of hos-
pitals. This yields
L2 (α) =
n1+n2  
i=n1+1
   1
0
Bi  
k=0
PBin
 
Mi,k;p
 
· PPoiss (k;(α · Bi)) · ν(p)dp
 
The likelihood of the full dataset is L(a)=L 1(a)·L2(a)
(cf. Figure 3). Maximizing this term with regard to a
will yield the maximum likelihood estimate for the true
incidence a.
3. Determination of confidence bounds for the global
incidence a Having obtained an estimate for the inci-
dence, we still need a confidence bounds as an assess-
ment for the precision of the estimate. Confidence
bounds are obtained with a bootstrap approach (see Fig-
ure 4[14]). It consists of executing B times the following
steps, yielding a sample of bootstrap incidences
ˆ α1,..., ˆ αB:
1. Random selection of a population model from
v0,..., v4 (with equal chance for each choice).
2. Generation of a bootstrap data sample from the
original data (M1,K 1),...,(Mn1,K n1), and Mn1+1,...,
Mn2 by sampling with replacement n1 and n2 obser-
vations from (M1,K 1),...,(Mn1,K n1)a n dM n1+1,...,
Mn2, respectively. Hence, the numbers of hospitals
with Ki available (or not) will be the same as in the
original data set.
3. Estimation of the incidence a from the bootstrap
data using the population model selected in the first
Figure 2 Empirical distribution function V(p) of the reporting
quota p for the age group below 15 years of age.
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bootstrap estimate ˆ αk.
The distribution of ˆ α1,..., ˆ αB closely resembles the
true distribution of ˆ α (for asymptotical convergence
results in similar cases see [14]). Hence, confidence
bounds on a can be determined from the quantiles of the
bootstrap distribution of ˆ α1,..., ˆ αB,e . g .t w o - s i d e dc o n f i -
dence bounds with nominal error probability b will be:
⎡
⎢
⎣ ˆ α −
⎛
⎜
⎝α  
(B+1)
 
1−
β
2
    −ˆ α
⎞
⎟
⎠, ˆ α −
⎛
⎜
⎝α  
(B+1)
β
2
   −ˆ α
⎞
⎟
⎠
⎤
⎥
⎦.
Here, ˆ α is the estimated IS incidence computed from
t h eo r i g i n a ld a t aa n dˆ α. ([x]) the x-th ordered sample of
the ˆ α1,..., ˆ αB bootstrap estimates. For our analysis we
use B = 1,000.
Results
Study population
Currently, there are 373 pediatric departments (includ-
ing departments for pediatric surgery) reporting data to
ESPED on any medical condition under observation.
Out of these 373 departments, 91 to 94% send monthly
reports back to ESPED headquarters, and 336 hospitals
were eligible to be included in the estimation of IS inci-
dence. Forty-seven hospitals were excluded because they
were not expected to treat IS cases due to their speciali-
zation as for example pediatric cardiac surgery units.
With regard to IS surveillance, 241 of the 336 depart-
ments reported cases of IS (71.7%). 209 of the departments
All hospitals (N = 
336)
Group 1: Hospitals with 
(Ki, Mi) available
(n1= 31)
Group 2: Other hospitals: 
only Mi available 
(n2= 305)
Estimate  
distribution V(p) of 
reporting quotes
Likelihood 
Function
Likelihood 
Function
Maximum Likelihood
Estimated incidence    
Maximum Likelihood Approach
1(,, ) LMKD
2 ˆ (, ( ) , ) LM VpD
ˆ() Vp
    12 ˆ argmax , , , , LMK LM Vp
D
DD ªº  ¬¼
ˆ D
Figure 3 The maximum likelihood method.
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completed follow-up questionnaire (86.7%).
From January 1, 2006 to December 31, 2007, 1,593
cases with IS were reported through the internet-based
reporting form (see Figure 5). For 1,353 reported IS
cases (84.9%) the follow-up questionnaires were
returned (i.e. cases referred to as completed cases). A
total of 153 cases (11.3% of the completed cases) were
either double reports or misreported as IS, and were
therefore excluded from the final analyses. Conse-
quently, the analysis was performed with 1,200 children
All hospitals (N = 336)
Group 1 hospitals: Group 2 hospitals:
Resample with
replacement
Estimate incidence from the
bootstrap data using maximum
likelihood
Bootstrap
Resample with
replacement
repeat B = 1000 times
Store      
Observed
data
Bootstrap
replication
step
Bootstrap sample Bootstrap sample Bootstrap
data
D
b D ˆ
Estimate the distribution
of     ( confidence intervals)
from
D ˆ
B D D ˆ , , ˆ1 
1 1 31 31 (,) , , (,)
bb bb MK MK
1 1 31 31 (,) , , (,) MK MK
32 373 ,,
bb MM
32 373 ,, MM
Figure 4 The bootstrap method.
Children with at least one event of definite  
IS (0<a<15): 1200 
0<a<2: 647
Children at least one event of definite 
IS in random sample for 31hospitals 
(0<a<15): 226
0<a<2: 129
Misreported/double reported cases: 153
Reported cases: 1593
Completed cases: 1353
Figure 5 Study population.
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tion criteria) occurrence of IS.
Calculation of the empirical distribution function of
underreporting
To get an unbiased estimation of the fraction of under-
reporting, a random sample of 46 hospitals out of the 336
hospitals was asked to re-evaluate all IS cases occurred in
the observation period from their records. Thirty-one hos-
pitals agreed to review their data. For these 31 hospitals
the number of pediatric beds and the degree of specializa-
tion were compared with the 305 remaining hospitals,
which yielded no statistically significant difference.
For the age group below 15 years of age, 9 of the 31
hospitals did not report any IS case to ESPED nor
revealed any case during the re-evaluation; therefore,
they did not contribute to the empirical distribution of
the reporting quota. This is the case for 10 hospitals for
the age group below two years of age and for 11 hospitals
for the age group below one year of age. A basic assump-
tion of the model is that it is possible to transfer the
empirical distribution of the reporting quotes of the ran-
dom sample to all hospitals. We further assume that the
reporting quote is randomly distributed over the hospi-
tals and is independent of characteristics of the hospital.
This seems to be justified as there is no significant or
relevant correlation between hospital specialization and
the reporting quota in all age groups (Spearman’sc o r r e -
lation coefficient is 0.181 (p = 0.430) for children below
15 years, 0.137, (p = 0.554) for children below 2 years,
and 0.136 (p = 0.569) for children below 1 year.).
The mean reporting quota was 41.1% for age below
15 years closely similar as for age below 2 years, where it
was 40.6%. For children aged below 1 year, it was 45.7%.
Annualized incidence of IS in Germany
An uncorrected annual incidence of IS in Germany for a
given age group was calculated as the ratio between the
annual number of IS cases reported via the ESPED
network and the number of children at risk, i.e. the
number of German children within the corresponding
age-group. This uncorrected incidence for IS in
Germany is a = 5.2/100,000 child-years for children
below 15 years, 23.8/100,000 child-years for children
below 2 years and 26.6/100,000 child-years for children
below 1 year (see Table 1).
Thus, a crude adjustment of the incidence for children
aged below 2 year using the underreporting quotas
reported above would yield 58.6% annual incidence of IS.
However, we are interested in a more precise estimate
which also includes confidence bounds. The maximum
likelihood estimate which incorporates underreporting
yields a mean value for a over all five population models
v0 to v4 of 10.4/100,000 child-years (95%CI: [8.6;12.1]
(see Table 2), for children of below 2 years of 51.5 (95%
CI [41.7;61.1], and for children below 1 year 60.4/100,000
(95%CI [48.3;72.1]).
The corrected incidence a and the corresponding 95%
confidence bands for the different population models v0,
v1, v2, v3 and v4 are very similar (see Table 2).
Discussion
Rotavirus vaccines were introduced in Germany 2006. In
order to evaluate whether or not these vaccines have an
impact on the risk of IS, it is essential to have accurate
baseline incidence estimates for IS in Germany.
Up to now, there are very few studies which used the
Brighton Collaboration’s case definition (first draft
2001 [1]). This study tries to fill this gap.
One retrospective study was performed in Singapore
[15] analyzing the IS incidence between 1997 and 2004.
While the authors report an average incidence of about
60/100,000 child-years for th ef i r s ty e a ro fl i f eo v e rt h e
whole period, it seems that the incidence is declining
after the official introduction of the Brighton criteria
from about 82 for 1997-2000 to about 34.6 for 2001-
2004. Justice et al. [16] - using a similar retrospective
study design - report a similar decline in IS incidence
Table 1 Annualized incidence of IS in Germany
Definite IS rate per 100,000 child years
Age (a) at
diagnosis
(year)
Number of definite
completed IS cases
Estimated IS cases
based on global
incidence**
Time at
risk
years
Population
at risk*
Uncorrected incidence based
reported cases (definite) via
ESPED
Corrected
incidence **
[95%-CI]
0 < a < 1 year 358 813 2 673,139 26.6 60.4 [48.3;72.1]
0<a<2
years
647 1,402 2 1,361,627 23.8 51.5 [41.7;61.1]
All (< 15
years)
1,200 2,371 2 11,441,367 5.2 10.4 [8.6;12.1]
*Population data for 2006 provided by the German Federal Office for Statistics.
**The corrected incidence is estimated by a maximum likelihood approach (taking into account the underreporting).
Uncorrected annual IS incidence a in Germany based on the ESPED data and corrected IS incidence estimated by a maximum likelihood approach which takes
into account the underreporting.
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to the incidence data in Singapore between 1997 and
2000. Again, this seems to be reasonably explained by
the introduction of new case definitions during this
period. The transferability of the results of the two
discussed studies is possibly limited because other stu-
dies indicate different IS rates depending on the ethnic
background. For example, Webby et al. [17] present
significantly different results for Aboriginal and non-
Aboriginal children in the Northern Territory of
Australia.
A limitation of the described studies - and also of sur-
veillance studies in general - is the potentially incom-
plete reporting of IS cases which may result in an
underestimation of the incidence.
S of a r ,t h eo n l yp r o s p e c t i v es t u d yo nI Sc o n s i d e r i n g
underreporting was performed in Switzerland [8]. In that
study the uncorrected IS incidence was refined by means
of a capture-recapture analysis. After correction, the inci-
dence of IS was estimated to be 56/100, 000 for children
below 1 year compared to 38/100,000 initially and 46/
100,000 for children below 2 years of age compared to 31
initially. It is worth noting that the method used in [8]
does not reflect a truly independent capture-recapture
approach in the classical sense as selections on the
re-evaluated hospitals and thus restrictions on the popu-
lation under risk were made. A truly independent cap-
ture-recapture approach would need to assess the whole
population under risk which was not the case. This may
result in a bias of the estimated reporting quote. Another
rather strict assumption was that the estimated reporting
quote was modeled to be constant and equal for all parti-
cipating hospitals in order to correct the incidence
estimate for IS. This seems unrealistic.
To avoid the practical problems associated with a truly
independent capture-recapture approach and to make
use of all available information, we estimated the distri-
bution of the reporting quota from a 10% random sam-
ple of all participating hospitals. The data from 31
hospitals was thus re-evaluated based on the ICD codes
and the Brighton criteria. The mean reporting quota
was 41.1% for children below 15 years (40.6% for
children below 2 years and 45.7% for children below
1 year), meaning less than half of the IS-cases were
actually reported. For the Swiss Pediatric Surveillance
Unit data [8], the reporting quote was estimated to be
about 68%.
For our modelling approach the empirical distribution
of the reporting quota was an essential part. We had
only 5 cases (2%) reported to ESPED which could not
be matched definitely to cases in the random sample,
which supports the assumption that the review proce-
dure is able to detect very close to 100% of all existing
cases of IS.
Another critical model assumption is the indepen-
dence of the reporting quota and the properties of a
hospital: our data set does not provide any evidence of a
violation of this assumption. Yet, a possible weakness of
our analysis could be that from the selected 41 hospitals
only 31 (67.4%) participated in the random sample.
However, this sample still seems to represent the
remaining hospitals in their known properties very well.
A strong point of the present study was the relatively
large number of 1200 cases, which provides a much
more solid database than, for example, the 288 cases of
the Swiss study. In addition, the maximum likelihood
approach used to estimate the corrected IS incidence a
takes into account the empirical distribution of the
reporting quota. The derived confidence intervals also
reflect the actual situation more accurately than just a
point estimate.
Our corrected incidence estimated here is 60.4/100,000
child-years for children below 1 year, 51.5/100,000 child-
years for children below 2 years of age, and 10.4/100,000
child-years for children below 15 years. These numbers
are a little higher than in the Swiss study, yet of the same
magnitude.
Conclusion
In summary, the present study provides a stable and
accurate estimation of IS incidence in Germany, cor-
rected for under-reporting. The robustness and accuracy
of the used ML model is demonstrated, on one hand, by
the very similar values of the corrected incidence a
Table 2 Maximum likelihood incidence a of IS in Germany
Population model Maximum likelihood incidence a per 100,000 child-years; 95% CI
0<a < 1 years 0<a < 2 years All
V0 60.2 [47.9;71.7] 51.5 [41.7;61.1] 10.7 [9.2;12.8]
V1 61.0 [49.5;73.3] 52.1 [42.9;62.3] 10.4 [8.6;12.2]
V2 60.2 [47.9;71.7] 51.2 [41.1;60.5] 10.2 [8.2;11.8]
V3 59.6 [46.7;70.5] 50.8 [40.3;59.7] 10.2 [8.2;11.8]
V4 61.0 [49.5;73.3] 51.9 [42.5;61.9] 10.3 [8.4;12.0]
Mean value 60.4 [48.3;72.1] 51.5 [41.7;61.1] 10.4 [8.6;12.1]
Maximum likelihood incidence a of IS in Germany and 95% confidence bounds for the population models v0, v1, v2, v3 and v4.
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els, and - on the other hand - by the narrow confidence
bounds for a obtained from the bootstrap approach.
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